The great majority of new, innovative medicines and vaccines marketed in the EU go through the centralized procedure, which includes scientific assessment by European Medicines Agency’s human medicines committee (the CHMP) and then a final decision by the European Commission. Decisions are valid in all EU member states as well as in the European Economic Area countries of Iceland, Liechtenstein and Norway.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?